Ultraviolet (UV)-induced DNA mutations generate genetic drivers of cutaneous melanoma and numerous neoantigens that can trigger anti-tumor immunity. Melanoma cells must therefore rapidly evade immune detection by modulating cell-autonomous epigenetic mechanisms and tumor–microenvironment interactions. Although angiogenesis typically facilitates immune infiltration, solid tumors increase vascularization while limiting immune cell entry. By comparing transcription factor (TF) expression across early-stage melanoma, naevi, and other cancers, we found that the homeodomain TF HOXD13 drives a melanoblast-like program upregulated in melanoma and strongly correlated with angiogenesis and immune cell exclusion. Using transcriptomics, 3D chromatin profiling, and in vivo models, we show that HOXD13 promotes tumor growth by enhancing angiogenesis and suppressing T-cell infiltration. HOXD13 orchestrates 3D enhancer–promoter contacts activating VEGFA, SEMA3A, and CD73, which remodel vasculature and elevate immunosuppressive adenosine. Consistently, HOXD13-induced tumor growth is reversed by combined VEGFR and adenosine receptor (AdR) inhibition, revealing a dual pro-angiogenic and immunosuppressive HOXD13 axis with therapeutic relevance.

Source:

Pietro Berico, Amanda Flores Yanke, Fatemeh Vand-Rajabpour, Catherine Do, Irving Simonin Wilmer, Ines Delclaux, Tara Muijlwijk, Robert Stagnitta, Martha Estefania Vázquez-Cruz, Theodore Sakellaropoulos, Matheus Ribeiro. Costa, Annie Cristhine Moraes Sousa-Squiavinato, Michelle Krogsgaard, Ata S. Moshiri, Iman Osman, Jane A. Skok, Patricia A. Possik, Carla Daniela Robles-Espinoza, Amanda W. Lund, Markus Schober, Eva Hernando; A targetable developmental program co-regulates angiogenesis and immune evasion in melanoma. Cancer Discov 2026; https://doi.org/10.1158/2159-8290.CD-24-1853

https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-24-1853/772176/A-targetable-developmental-program-co-regulates